Management of Sulfonylureas and Optimized Diabetes Therapy in Advanced CKD

Hypoglycemia Risk with Sulfonylureas

GLP‑1 Receptor Agonist (Semaglutide) Use

SGLT2 Inhibitor Consideration

Monitoring of Renal Function

Insulin Degludec Dosing

Gradual Glimepiride Withdrawal

Contraindicated and Limited‑Use Medications

All statements are derived from KDIGO clinical practice guidelines (2020, 2022) and supporting peer‑reviewed evidence.